BiotechTube

Itacitinib + Corticosteroids

Phase 1/2Terminated
0 watching 0 views this week💤 Quiet
38
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acute Graft-versus-host Disease

Conditions

Acute Graft-versus-host Disease

Trial Timeline

Dec 31, 2019 → Feb 17, 2020

NCT ID
NCT03721965

About Itacitinib + Corticosteroids

Itacitinib + Corticosteroids is a phase 1/2 stage product being developed by Incyte for Acute Graft-versus-host Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT03721965. Target conditions include Acute Graft-versus-host Disease.

Hype Score Breakdown

Clinical
13
Activity
8
Company
7
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT03721965Phase 1/2Terminated

Competing Products

20 competing products in Acute Graft-versus-host Disease

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
25
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
44
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
TRV130TrevenaPhase 3
69
TRV130 + Morphine + PlaceboTrevenaPhase 2
44
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
SPT-07A injectionSinopharmPhase 3
76
PRGN-3006 T CellsPrecigenPhase 1
28
BisantreneRace OncologyPhase 2
44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
25
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
44
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
33
ZN-d5Zentalis PharmaceuticalsPhase 1
25
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
25
LY2523355Eli LillyPhase 1
33
TomivosertibeFFECTOR TherapeuticsPhase 1
25
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
77

Other Products from Incyte

ruxolitinib creamApproved
82
Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3
74
Povorcitinib + PlaceboPhase 3
74
Ruxolitinib Cream + Vehicle CreamPhase 3
74
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3
74